Achieve Life Sciences strengthens its executive suite with a new CFO appointment, signaling a strategic focus on the upcoming commercialization phase for its smoking cessation drug, cytisinicline.
Appointment of a CFO with public company and commercial pharma experience is a routine leadership change, neutral in the absence of financial guidance or operational updates.
Achieve Life Sciences has appointed a new Chief Financial Officer to bolster its leadership team as the company advances toward the potential commercialization of its lead candidate, cytisinicline. The incoming executive brings extensive experience in public company financial management and commercial pharmaceutical operations to support the firm's strategic growth.
The new CFO is tasked with leveraging their experience in commercial pharma and business development to prepare Achieve Life Sciences for the potential commercial launch of cytisinicline.